Does the media refer more to ARAY or MBOT?

In the previous week, Microbot Medical had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for Microbot Medical and 1 mentions for Accuray. Microbot Medical's average media sentiment score of 0.43 beat Accuray's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ARAY or KEQU?

Accuray currently has a consensus target price of $2.00, suggesting a potential upside of 786.92%. Given Accuray's higher probable upside, research analysts clearly believe Accuray is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accuray 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ARAY or KEQU?

In the previous week, Kewaunee Scientific had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for Kewaunee Scientific and 1 mentions for Accuray. Kewaunee Scientific's average media sentiment score of 0.19 beat Accuray's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kewaunee Scientific 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, LNSR or ARAY?

LENSAR has higher earnings, but lower revenue than Accuray. LENSAR is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $60.26M 1.46 -$34.28M -$0.33 N/A Accuray $401.95M 0.07 -$49.19M -$0.40 N/A

Is LNSR or ARAY more profitable?

LENSAR has a net margin of 57.57% compared to Accuray's net margin of -12.24%. Accuray's return on equity of -97.85% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Accuray -12.24% -97.85% -10.82%

Is ECOR or ARAY more profitable?

Accuray has a net margin of -12.24% compared to electroCore's net margin of -39.96%. Accuray's return on equity of -97.85% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -39.96% -1,956.38% -81.35% Accuray -12.24% -97.85% -10.82%

Does the media prefer ECOR or ARAY?

In the previous week, electroCore had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for electroCore and 1 mentions for Accuray. electroCore's average media sentiment score of 1.45 beat Accuray's score of 0.00 indicating that electroCore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment electroCore 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, HYPR or ARAY?

Hyperfine has higher earnings, but lower revenue than Accuray. Hyperfine is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 7.35 -$35.57M -$0.38 N/A Accuray $401.95M 0.07 -$49.19M -$0.40 N/A

Is HYPR or ARAY more profitable?

Accuray has a net margin of -12.24% compared to Hyperfine's net margin of -210.75%. Accuray's return on equity of -97.85% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% Accuray -12.24% -97.85% -10.82%

Does the media prefer HYPR or ARAY?

In the previous week, Hyperfine had 2 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Hyperfine and 1 mentions for Accuray. Accuray's average media sentiment score of 0.00 beat Hyperfine's score of -0.02 indicating that Accuray is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Accuray (ARAY) Competitors

$0.23 0.00 (-1.96%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.23 +0.00 (+1.55%)

As of 05:35 AM Eastern

Compare

ARAY vs. MBOT, KEQU, LNSR, ECOR, and HYPR

Should you buy Accuray stock or one of its competitors? Accuray's main competitors and comparable companies include Microbot Medical (MBOT), Kewaunee Scientific (KEQU), LENSAR (LNSR), electroCore (ECOR), and Hyperfine (HYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Accuray compare to Microbot Medical?

Accuray (NASDAQ:ARAY) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Microbot Medical has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Microbot Medical's return on equity of -21.87% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Microbot Medical	N/A	-21.87%	-20.76%

Accuray has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

64.1% of Accuray shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 2.4% of Accuray shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Accuray presently has a consensus price target of $2.00, suggesting a potential upside of 786.92%. Microbot Medical has a consensus price target of $6.38, suggesting a potential upside of 386.64%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has lower revenue, but higher earnings than Accuray. Microbot Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A

In the previous week, Microbot Medical had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for Microbot Medical and 1 mentions for Accuray. Microbot Medical's average media sentiment score of 0.43 beat Accuray's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Microbot Medical beats Accuray on 9 of the 15 factors compared between the two stocks.

How does Accuray compare to Kewaunee Scientific?

Accuray (NASDAQ:ARAY) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Kewaunee Scientific had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for Kewaunee Scientific and 1 mentions for Accuray. Kewaunee Scientific's average media sentiment score of 0.19 beat Accuray's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kewaunee Scientific	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kewaunee Scientific has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A
Kewaunee Scientific	$282M	0.35	$9.62M	$2.76	12.33

Kewaunee Scientific has a net margin of 2.97% compared to Accuray's net margin of -12.24%. Kewaunee Scientific's return on equity of 11.61% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Kewaunee Scientific	2.97%	11.61%	4.82%

64.1% of Accuray shares are held by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are held by institutional investors. 2.4% of Accuray shares are held by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Accuray has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Accuray currently has a consensus target price of $2.00, suggesting a potential upside of 786.92%. Given Accuray's higher probable upside, research analysts clearly believe Accuray is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kewaunee Scientific beats Accuray on 11 of the 15 factors compared between the two stocks.

How does Accuray compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Accuray had 1 more articles in the media than LENSAR. MarketBeat recorded 1 mentions for Accuray and 0 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 equaled Accuray'saverage media sentiment score.

Company	Overall Sentiment
LENSAR	Neutral
Accuray	Neutral

LENSAR has higher earnings, but lower revenue than Accuray. LENSAR is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$60.26M	1.46	-$34.28M	-$0.33	N/A
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A

LENSAR has a net margin of 57.57% compared to Accuray's net margin of -12.24%. Accuray's return on equity of -97.85% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Accuray	-12.24%	-97.85%	-10.82%

LENSAR has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Accuray has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

LENSAR currently has a consensus price target of $11.50, indicating a potential upside of 60.84%. Accuray has a consensus price target of $2.00, indicating a potential upside of 786.92%. Given Accuray's higher probable upside, analysts plainly believe Accuray is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

40.2% of LENSAR shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 65.8% of LENSAR shares are held by insiders. Comparatively, 2.4% of Accuray shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

LENSAR beats Accuray on 8 of the 15 factors compared between the two stocks.

How does Accuray compare to electroCore?

electroCore (NASDAQ:ECOR) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 7.8% of electroCore shares are owned by company insiders. Comparatively, 2.4% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

electroCore has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Accuray has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

electroCore currently has a consensus target price of $18.00, indicating a potential upside of 57.62%. Accuray has a consensus target price of $2.00, indicating a potential upside of 786.92%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, electroCore had 3 more articles in the media than Accuray. MarketBeat recorded 4 mentions for electroCore and 1 mentions for Accuray. electroCore's average media sentiment score of 1.45 beat Accuray's score of 0.00 indicating that electroCore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
electroCore	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

electroCore has higher earnings, but lower revenue than Accuray. electroCore is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$36.97M	2.79	-$13.97M	-$1.66	N/A
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A

Accuray has a net margin of -12.24% compared to electroCore's net margin of -39.96%. Accuray's return on equity of -97.85% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	-1,956.38%	-81.35%
Accuray	-12.24%	-97.85%	-10.82%

Summary

Accuray beats electroCore on 9 of the 16 factors compared between the two stocks.

How does Accuray compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 2.4% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperfine has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Accuray has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Hyperfine presently has a consensus price target of $2.03, indicating a potential upside of 157.38%. Accuray has a consensus price target of $2.00, indicating a potential upside of 786.92%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Hyperfine had 2 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Hyperfine and 1 mentions for Accuray. Accuray's average media sentiment score of 0.00 beat Hyperfine's score of -0.02 indicating that Accuray is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Accuray has a net margin of -12.24% compared to Hyperfine's net margin of -210.75%. Accuray's return on equity of -97.85% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
Accuray	-12.24%	-97.85%	-10.82%

Hyperfine has higher earnings, but lower revenue than Accuray. Hyperfine is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.35	-$35.57M	-$0.38	N/A
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A

Summary

Hyperfine and Accuray tied by winning 8 of the 16 factors compared between the two stocks.

Get Accuray News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAY vs. The Competition

Export

Metric	Accuray	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.47M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.56	25.26	274.08	25.69
Price / Sales	0.07	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.64	5.78	10.47	6.32
Net Income	-$49.19M	$151.55M	$3.49B	$359.73M
7 Day Performance	-6.43%	-0.01%	-0.67%	0.17%
1 Month Performance	-16.97%	-3.53%	-3.17%	-3.27%
1 Year Performance	-87.26%	6.37%	15.14%	5.58%

Accuray Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAY Accuray	1.7539 of 5 stars	$0.23 -2.0%	$2.00 +786.9%	-86.9%	$27.47M	$401.95M	N/A	809	Gap Up
MBOT Microbot Medical	2.1431 of 5 stars	$1.46 +0.7%	$6.38 +336.6%	-62.4%	$98.06M	$346K	N/A	20	News Coverage
KEQU Kewaunee Scientific	0.824 of 5 stars	$36.80 +5.0%	N/A	-21.7%	$97.51M	$277.22M	12.32	1,231
LNSR LENSAR	2.6975 of 5 stars	$7.86 +0.6%	$11.50 +46.4%	-42.5%	$95.66M	$60.26M	N/A	110	Positive News
ECOR electroCore	3.1619 of 5 stars	$9.75 -0.2%	$18.00 +84.7%	+120.9%	$87.99M	$32.03M	N/A	50	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAY) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accuray (ARAY) Competitors

ARAY vs. MBOT, KEQU, LNSR, ECOR, and HYPR

How does Accuray compare to Microbot Medical?

Summary

How does Accuray compare to Kewaunee Scientific?

Summary

How does Accuray compare to LENSAR?

Summary

How does Accuray compare to electroCore?

Summary

How does Accuray compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accuray (ARAY) Competitors

ARAY vs. MBOT, KEQU, LNSR, ECOR, and HYPR

How does Accuray compare to Microbot Medical?

Is ARAY or MBOT more profitable?

Which has more volatility and risk, ARAY or MBOT?

Do institutionals & insiders hold more shares of ARAY or MBOT?

Do analysts prefer ARAY or MBOT?

Which has stronger valuation & earnings, ARAY or MBOT?

Does the media refer more to ARAY or MBOT?

Summary

How does Accuray compare to Kewaunee Scientific?

Does the media refer more to ARAY or KEQU?

Which has better earnings & valuation, ARAY or KEQU?

Is ARAY or KEQU more profitable?

Do institutionals & insiders hold more shares of ARAY or KEQU?

Which has more risk & volatility, ARAY or KEQU?

Do analysts prefer ARAY or KEQU?

Summary

How does Accuray compare to LENSAR?

Does the media favor LNSR or ARAY?

Which has better valuation and earnings, LNSR or ARAY?

Is LNSR or ARAY more profitable?

Which has more volatility & risk, LNSR or ARAY?

Do analysts rate LNSR or ARAY?

Do institutionals & insiders have more ownership in LNSR or ARAY?

Summary

How does Accuray compare to electroCore?

Do insiders & institutionals believe in ECOR or ARAY?

Which has more volatility & risk, ECOR or ARAY?

Do analysts prefer ECOR or ARAY?

Does the media prefer ECOR or ARAY?

Which has better earnings and valuation, ECOR or ARAY?

Is ECOR or ARAY more profitable?

Summary

How does Accuray compare to Hyperfine?

Do insiders and institutionals believe in HYPR or ARAY?

Which has more volatility & risk, HYPR or ARAY?

Do analysts recommend HYPR or ARAY?

Does the media prefer HYPR or ARAY?

Is HYPR or ARAY more profitable?

Which has better valuation & earnings, HYPR or ARAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools